alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–24 of 24 studies in Cognitive tests and assessment · free to read · tagged Risk Factors · 31,380 in the whole library · How the 0–100 score works

Download bibliography of these 24 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

What “Cognitive tests and assessment” covers

Cognitive tests and assessment — Memory and thinking tests, screening tools and rating scales: how well they measure what they claim to.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Blood cholesterol in late-life and cognitive decline: a longitudinal study of the Chinese elderly

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Molecular neurodegeneration 2017-03-07

We thus examined whether higher blood cholesterol concentrations were associated with faster cognitive decline in a community-based longitudinal study of Chinese elderly. 4 key findings →

Design: longitudinal study Participants: 90 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies

✓ Peer-reviewed alzhub usefulness score 59 out of 100. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2012-02-27

The role of atrial fibrillation in cognitive impairment and dementia, independent of stroke, is uncertain. 4 key findings →

Design: post-hoc analysis Participants: 31,506 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Cognitive decline in patients with dementia as a function of depression

✓ Peer-reviewed alzhub usefulness score 56 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2011-04-01

There is evidence that major depression increases the risk for dementia, but there is conflicting evidence as to whether depression may accelerate cognitive decline in dementia. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Curcumin-Rich Curry Consumption Is Associated with Lower Risk of Cognitive Decline and Incidence of Mild Cognitive Impairment or Dementia: An Asian Population-Based Study

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Nutrients 2025-07-30

A decreasing linear trend was observed between higher levels of curry consumption and cognitive decline (p = 0.037). 4 key findings →

Design: cohort study Participants: 2,920 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Physical Frailty, Cognitive Impairment, and the Risk of Neurocognitive Disorder in the Singapore Longitudinal Ageing Studies

✓ Peer-reviewed alzhub usefulness score 53 out of 100. The journals of gerontology. Series A, Biological sciences and medical sciences 2017-03-01

The independent and combined effects of physical and cognitive domains of frailty in predicting the development of mild cognitive impairment (MCI) or dementia are not firmly established. 2 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Risk factors of caregiver burden among patients with Alzheimer's disease or related disorders: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of Alzheimer's disease : JAD 2015-01-01

Caregivers play a major role in the care of patients with dementia and are themselves at higher risk of disease. 4 key findings →

Participants: 548 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A New Computer-Based Cognitive Measure for Early Detection of Dementia Risk (Japan Cognitive Function Test): Validation Study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of medical Internet research 2025-02-14

Significant hazard ratios (HRs) for dementia incidence were found using the MMSE cutoff between 23 and 24 point (HR 1.93, 95% CI 1.13-3.27) and the J-Cog cutoff between 43 and 44 points (HR 2.42, 95% CI 1.50-3.93). 4 key findings →

Design: case-control study Participants: 100 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Elevated gonadotropins and risk of dementia in Chinese adults aged over 80: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Frontiers in Aging Neuroscience 2025-10-17

Elevated FSH and reduced LH may be associated with poorer cognition and an increased risk of AD-D in very old Chinese adults, particularly in males. 5 key findings →

Design: cross-sectional Participants: 509 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Statins, cholesterol and cognition at the time of Alzheimer's disease diagnosis: A cross-sectional study from the Swedish registry for cognitive/dementia disorders

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of Alzheimer s Disease Reports 2025-01-01

We included 3074 AD patients (mean age 78.1 years; 59.4% women), of whom 1028 used statins (79.6% simvastatin, 20.4% atorvastatin). 5 key findings →

Design: cross-sectional Participants: 3,074 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Montreal Cognitive Assessment is superior to the Mini-Mental State Examination in detecting patients at higher risk of dementia

✓ Peer-reviewed alzhub usefulness score 49 out of 100. International psychogeriatrics 2012-06-12

Memory clinic patients were administered the MoCA, MMSE, and a comprehensive formal neuropsychological battery. 4 key findings →

Participants: 36 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A dual-pathway model of depression's mediation between chronic pain and dementia

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Experimental Gerontology 2026-02-11

After adjusting for potential confounders, multivariable logistic regression models revealed that the prevalence of dementia was significantly higher in individuals with chronic pain than in those without. 3 key findings →

Design: cross-sectional Participants: 1,096 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Associations of cholinergic white matter hyperintensity volume with cognitive decline and incident dementia in older adults: a cohort study

✓ Peer-reviewed alzhub usefulness score 49 out of 100. BMC Geriatrics 2025-10-10

During follow-up, cholinergic WMHV was associated with an annual decline of Mini-Mental State Examination (MMSE) (β coefficient, -0.239; P = 0.004), and incident dementia (HR = 3.54; 95%CI: 2.05-6.10). 5 key findings →

Design: cross-sectional Participants: 751 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Schizophrenia and dementia across the lifespan: epidemiological links, cognitive trajectories, and the pathophysiological interplay

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in Neurology 2026-04-07

Epidemiological studies consistently indicate a two- to threefold increased risk of dementia among individuals with schizophrenia, although estimates vary due to diagnostic and ascertainment biases. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cognitive trajectories and dementia risk in patients with schizophrenia spectrum versus affective disorders

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Psychological Medicine 2025-01-01

= 1,217; 65.0 years) showed earlier initial MMSE scores (by 6.1 years, 95% CI = 5.2-7.0), earlier dementia diagnoses (by 2.3 years, 95% CI = 0.9-3.7) but lower dementia risk (adjusted HR = 0.81; 95% CI = 0.69-0.95). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Severity and Prognosis of Vascular Dementia in Patients with Acute Cerebral Infarction Combined with H-Type Hypertension and Its Correlation with Uric Acid Levels

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Neuropsychiatric Disease and Treatment 2025-06-01

The observation group had significantly higher blood uric acid levels than the control group (P<0.05). 5 key findings →

Participants: 84 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events